The standard clinical practice of managing the non-small cell lung cancer(NSCLC)with epider-mal growth factor receptor(EGFR)exon 20 insertion(ex20ins)mutations was elaborated in Chinese expert consensus on non-small cell lung cancer with EGFR exon 20 insertion mutations(2023 edition),and this rare subset has gradually attracted attention recently.With the deepening of treatment area exploration and the approval of new targeted drugs,there are more options for the diagnosis and treatment of EGFR ex20ins positive NSCLC patients.Therefore,based on the previous version of consensus,the expert panel has updated this consensus on the standardized clinical diagnosis and treatment of EGFR ex20ins mutation NSCLC through reference to literature and clinical data,and combined with the experts'own clinical experience.The updated recommendations includes disease congnition,testing methods,therapy and recent relevant clinical trials for NSCLC patients with EGFR ex20ins mutation,in order to provide better medication reference for clinical physicians.

Corona virus disease 2019(COVID-19)infection has become a major public health issue affecting human health.The main goal of epidemic prevention and control at the current stage in China is to"protect people's health and prevent severe cases".Patients with lung cancer who receive antitumor therapy have low immunity,and the risk of severe illness and death once infected is much higher than healthy people,so they are vulnerable to COVID-19 infection.At present,less attention has been paid to the prevention and treatment of COVID-19 infection in patients with lung cancer in domestic guidelines and consensus.Based on the published data in China and abroad,we proposed recommendations and formed expert consensus on the vaccination of COVID-19,the use of neutralizing antibodies and small molecule antiviral drugs for patients with lung cancer,for physician's reference.

For advanced non-small cell lung cancer(NSCLC)patients with negative driver gene mutations,chemo-therapy has always been the standard treatment option,and immune checkpoint inhibitors(ICIs)provide other treatment op-tion for these patients.At present,the first-line treatment can choose chemotherapy,anti-angiogenic drugs or immunotherapy.Although the initial treatment can achieve a certain clinical curative effect,disease progression or treatment failure is eventually unavoidable.The second-line and subsequent treatments have poor efficacy and more effective drugs are needed clinically.An expert panel of respiratory medicine,pathology and medical oncology organized by Expert Committee on Non-small Cell Lung Cancer of the Chinese Society of Clinical Oncology conducted an in-depth discussion on evidences of clinical studies for second-line treatment of NSCLC patients with negative driver gene mutations,aiming to provide guidances for Chinese clini-cians in choosing second-line treatment for NSCLC patients with negative driver gene mutations.